Literature DB >> 30054906

Prevention of contrast-induced nephropathy by adequate hydration combined with isosorbide dinitrate for patients with renal insufficiency and congestive heart failure.

Geng Qian1, Chang-Fu Liu1, Jun Guo1, Wei Dong1, Jin Wang1, Yundai Chen1.   

Abstract

BACKGROUND: Adequate hydration remains the mainstay of contrast-induced nephropathy prevention, and nitrates could reduce cardiac preload. HYPOTHESIS: This study aimed to explore the adequate hydration with nitrates for patients with chronic kidney disease (CKD) and congestive heart failure (CHF) to reduce the risk of contrast-induced nephropathy (CIN) and at the same time avoid the acute heart failure.
METHODS: Three hundred and ninty-four consecutive patients with CKD and CHF undergoing coronary procedures were randomized to either adequate hydration with nitrates (n = 196) or to routine hydration (control group; n = 198). The adequate hydration group received continuous intravenous infusion of isosorbide dinitrate combined with intravenous infusion of isotonic saline at a rate of 1.5 mL/kg/h during perioperative period. The definition of CIN was a 25% or 0.5 mg/dL rise in serum creatinine over baseline. This trial is registered with www.clinicaltrials.gov, number NCT02718521.
RESULTS: Baseline characteristics were well-matched between the two groups. CIN occurred less frequently in adequate hydration group than the control group (12.8% vs 21.2%; P = 0.018). The incidence of acute heart failure did not differ between the two groups (8 [4.08%] vs 6[3.03%]; P = 0.599). Cumulative major adverse events (death, myocardial infarction, stoke, hospitalization for acute heart failure) during the 90-day follow-up were lower in the adequate hydration with nitrates group (P = 0.002).
CONCLUSIONS: Adequate hydration with nitrates can safely and effectively reduce the risk of CIN in patients with CKD and CHF.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  congestive heart failure; contrast-induced nephropathy; nitrates

Mesh:

Substances:

Year:  2019        PMID: 30054906      PMCID: PMC6436482          DOI: 10.1002/clc.23023

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  25 in total

1.  Contrast-Induced Nephropathy (CIN) Consensus Working Panel: executive summary.

Authors:  Peter A McCullough; Fulvio Stacul; Christoph R Becker; Andy Adam; Norbert Lameire; James A Tumlin; Charles J Davidson
Journal:  Rev Cardiovasc Med       Date:  2006       Impact factor: 2.930

2.  Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease.

Authors:  Andrew D Rule; Timothy S Larson; Erik J Bergstralh; Jeff M Slezak; Steven J Jacobsen; Fernando G Cosio
Journal:  Ann Intern Med       Date:  2004-12-21       Impact factor: 25.391

3.  A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity.

Authors:  Hariprasad S Trivedi; Harold Moore; Samer Nasr; Kul Aggarwal; Alok Agrawal; Punit Goel; John Hewett
Journal:  Nephron Clin Pract       Date:  2003-01

4.  Reply: Intravenous hydration (with or without rosuvastatin) should remain the cornerstone of the prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease.

Authors:  Yaling Han
Journal:  J Am Coll Cardiol       Date:  2014-07-22       Impact factor: 24.094

5.  Prevention of contrast-induced nephropathy by adequate hydration combined with isosorbide dinitrate for patients with renal insufficiency and congestive heart failure.

Authors:  Geng Qian; Chang-Fu Liu; Jun Guo; Wei Dong; Jin Wang; Yundai Chen
Journal:  Clin Cardiol       Date:  2019-01-07       Impact factor: 2.882

6.  Prevention of Contrast-Induced Nephropathy by Central Venous Pressure-Guided Fluid Administration in Chronic Kidney Disease and Congestive Heart Failure Patients.

Authors:  Geng Qian; Zhenhong Fu; Jun Guo; Feng Cao; Yundai Chen
Journal:  JACC Cardiovasc Interv       Date:  2015-12-09       Impact factor: 11.195

7.  Nephrotoxic effects in high-risk patients undergoing angiography.

Authors:  Peter Aspelin; Pierre Aubry; Sven-Göran Fransson; Ruth Strasser; Roland Willenbrock; Knut Joachim Berg
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

8.  The use of nitrates in the prevention of contrast-induced nephropathy in patients hospitalized after undergoing percutaneous coronary intervention.

Authors:  Julio G Peguero; Vertilio Cornielle; Sabas I Gomez; Omar M Issa; Todd B Heimowitz; Orlando Santana; Robert C Goldszer; Gervasio A Lamas
Journal:  J Cardiovasc Pharmacol Ther       Date:  2013-12-23       Impact factor: 2.457

9.  Contrast media induced nephropathy: definition, incidence, outcome, pathophysiology, risk factors and prevention.

Authors:  T Feldkamp; A Kribben
Journal:  Minerva Med       Date:  2008-04       Impact factor: 4.806

10.  Furosemide with saline hydration for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a meta-analysis of randomized controlled trials.

Authors:  Nana Duan; Jiegang Zhao; Zhuanzhen Li; Pingshuan Dong; Shaoxin Wang; Yuwei Zhao; Liping Wang; Hongyun Wang
Journal:  Med Sci Monit       Date:  2015-01-23
View more
  3 in total

1.  Prevention of contrast-induced nephropathy by adequate hydration combined with isosorbide dinitrate for patients with renal insufficiency and congestive heart failure.

Authors:  Geng Qian; Chang-Fu Liu; Jun Guo; Wei Dong; Jin Wang; Yundai Chen
Journal:  Clin Cardiol       Date:  2019-01-07       Impact factor: 2.882

2.  Volume Status, a Novel Marker of Contrast Induced Acute Kidney Injury in Acute Heart Failure Undergoing Coronary Angiography?

Authors:  Sung Woo Lee
Journal:  Int J Heart Fail       Date:  2020-01-20

3.  Renal protective effect of sodium ferulate on pulmonary hypertension patients undergoing computed tomography pulmonary angiography.

Authors:  Ying Zhao; Haiyan Wang; Jiayu Zhao; Xun Wang; Yanbo Wang; Wei Li; Tingting Song; Guozhen Hao; Xianghua Fu; Xinshun Gu
Journal:  Pulm Circ       Date:  2020-10-26       Impact factor: 3.017

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.